Skip to content
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Century Therapeutics, Inc. IPSC

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$109.2M
▲ 1556.8% YoY
$-9.6M
$-104.7M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Century Therapeutics, Inc. develops allogeneic pluripotent stem cell-derived cell therapy products for autoimmune diseases, including type 1 diabetes, and cancer. Its lead product candidate, CNTY-813, is an iPSC-derived beta islet cell replacement therapy engineered with the company's Allo-Evasion technology. It is prioritizing clinical development of CNTY-101, a CAR-iNK cell therapy with six precision gene edits, in CARAMEL, a Phase 1/2 investigator sponsored trial that is enrolling and dosing patients with B-cell-mediated autoimmune diseases. It is also conducting IND-enabling studies for CNTY-308, a CD19-targeted CD4+/CD8+ ab CAR-iT cell therapy engineered with Allo-Evasion 5.0 and being developed as a potential treatment for B-cell-mediated diseases. Its principal executive offices, along with its office and laboratory space, are located in Philadelphia, Pennsylvania, and it also operates a cell therapy manufacturing facility in Branchburg, New Jersey.

Written from the business description in Century Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth

USD 109.2M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 109.2 · Net income -9.6
50M100M-50M-100M
202020232025
Compound annual growth
+175.9%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−9 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -15.8%
-2000%-4000%-6000%
202020222025
ROE
FY2025 · ROE -6.0%
-20%-40%-60%
202020222025
Three returns, three denominators.

Each USD of equity lost 6 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -104.7
-50M-100M
202020222025

Total assetsUSD 223.7M
EquityUSD 158.9M
CashUSD 61.9M
Current ratio5.97×

Equity funds 71% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
IPSC, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.10.00.00.0◌◌
Operating income $B−0.0−0.1−0.1−0.1−0.1−0.1
EBITDA $B−0.0−0.1−0.1−0.1−0.1−0.1
Income tax $B−0.00.00.00.00.0◌
Net income $B−0.0−0.1−0.1−0.1−0.1−0.1
Free cash flow $B−0.1−0.1−0.1−0.0−0.1−0.1
EPS, diluted $−0.14−1.61−2.30−2.96−2.96−7.16
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−6.0−73.1−56.1−37.5——
Shares out B0.090.090.060.060.060.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 1 failure in 24 reconciliationsAUDITED

Reconciled in 5 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image